Karen M. Anderson Sells 30,526 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Karen M. Anderson sold 30,526 shares of the business’s stock in a transaction on Friday, February 7th. The shares were sold at an average price of $19.03, for a total transaction of $580,909.78. Following the sale, the insider now directly owns 54,322 shares of the company’s stock, valued at $1,033,747.66. This represents a 35.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Centessa Pharmaceuticals Stock Up 4.3 %

Shares of Centessa Pharmaceuticals stock opened at $18.00 on Thursday. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The stock has a market cap of $2.37 billion, a price-to-earnings ratio of -11.76 and a beta of 1.53. The firm’s 50-day moving average is $16.80 and its two-hundred day moving average is $15.56. Centessa Pharmaceuticals plc has a 1 year low of $7.75 and a 1 year high of $19.09.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.05. As a group, research analysts expect that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Institutional Trading of Centessa Pharmaceuticals

A number of hedge funds have recently bought and sold shares of CNTA. Janus Henderson Group PLC purchased a new position in shares of Centessa Pharmaceuticals in the 3rd quarter valued at $20,698,000. Franklin Resources Inc. boosted its position in Centessa Pharmaceuticals by 99.1% during the third quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company’s stock valued at $38,360,000 after purchasing an additional 1,145,823 shares in the last quarter. Point72 Asset Management L.P. grew its stake in Centessa Pharmaceuticals by 54.1% in the third quarter. Point72 Asset Management L.P. now owns 2,715,663 shares of the company’s stock valued at $43,423,000 after purchasing an additional 953,659 shares during the last quarter. Baker BROS. Advisors LP raised its holdings in Centessa Pharmaceuticals by 123.4% in the third quarter. Baker BROS. Advisors LP now owns 1,227,178 shares of the company’s stock worth $19,623,000 after purchasing an additional 677,966 shares in the last quarter. Finally, Ally Bridge Group NY LLC purchased a new stake in shares of Centessa Pharmaceuticals during the third quarter valued at about $4,951,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Guggenheim reiterated a “buy” rating on shares of Centessa Pharmaceuticals in a report on Monday. TD Cowen assumed coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating for the company. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $25.83.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.